Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
Journal of Medicinal Chemistry
|
February 6, 2015
Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach
Hasane Ratni, Mark Rogers-Evans, Caterina Bissantz, et al.
Iscience
|
July 7, 2023
Behavioral analysis through the lifespan of <i>disc1</i> mutant zebrafish identifies defects in sensorimotor transformation
Brock R Pluimer, Devin L Harrison, Chanon Boonyavairoje, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 6, 2013
Highly potent and selective cannabinoid receptor 2 agonists: initial hit optimization of an adamantyl hit series identified from high-through-put screening
Matthias Nettekoven, Jürgen Fingerle, Uwe Grether, et al.
Journal of Medicinal Chemistry
|
January 18, 2020
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder
Patrick Schnider, Caterina Bissantz, Andreas Bruns, et al.
Molecules (Basel, Switzerland)
|
September 22, 2019
Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis
Richard Frederick Porter, Anna-Maria Szczesniak, James Thomas Toguri, et al.
Chemmedchem
|
August 1, 2015
Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases
Matthias Nettekoven, Jean-Michel Adam, Stefanie Bendels, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 6, 2013
BACE1 inhibitors: a head group scan on a series of amides
Thomas J Woltering, Wolfgang Wostl, Hans Hilpert, et al.
The EMBO Journal
|
June 8, 2018
NF-κB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS
Najwa Ouali Alami, Christine Schurr, Florian Olde Heuvel, et al.
Journal of Medicinal Chemistry
|
April 18, 2013
β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease
Hans Hilpert, Wolfgang Guba, Thomas J Woltering, et al.
Journal of Medicinal Chemistry
|
March 14, 2008
Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity
Leo Alig, Jochem Alsenz, Mirjana Andjelkovic, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
Journal of Medicinal Chemistry
|
February 6, 2015
Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach
Hasane Ratni, Mark Rogers-Evans, Caterina Bissantz, et al.
Iscience
|
July 7, 2023
Behavioral analysis through the lifespan of <i>disc1</i> mutant zebrafish identifies defects in sensorimotor transformation
Brock R Pluimer, Devin L Harrison, Chanon Boonyavairoje, et al.
Bioorganic & Medicinal Chemistry Letters
|
February 6, 2013
Highly potent and selective cannabinoid receptor 2 agonists: initial hit optimization of an adamantyl hit series identified from high-through-put screening
Matthias Nettekoven, Jürgen Fingerle, Uwe Grether, et al.
Journal of Medicinal Chemistry
|
January 18, 2020
Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder
Patrick Schnider, Caterina Bissantz, Andreas Bruns, et al.
Molecules (Basel, Switzerland)
|
September 22, 2019
Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis
Richard Frederick Porter, Anna-Maria Szczesniak, James Thomas Toguri, et al.
Chemmedchem
|
August 1, 2015
Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases
Matthias Nettekoven, Jean-Michel Adam, Stefanie Bendels, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 6, 2013
BACE1 inhibitors: a head group scan on a series of amides
Thomas J Woltering, Wolfgang Wostl, Hans Hilpert, et al.
The EMBO Journal
|
June 8, 2018
NF-κB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS
Najwa Ouali Alami, Christine Schurr, Florian Olde Heuvel, et al.
Journal of Medicinal Chemistry
|
April 18, 2013
β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease
Hans Hilpert, Wolfgang Guba, Thomas J Woltering, et al.
Journal of Medicinal Chemistry
|
March 14, 2008
Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity
Leo Alig, Jochem Alsenz, Mirjana Andjelkovic, et al.
Page
of 3